|
|
Volumn 158, Issue 12, 2001, Pages 2071-2074
|
|
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ICOSAPENTAENOIC ACID ETHYL ESTER;
NEUROLEPTIC AGENT;
OMEGA 3 FATTY ACID;
PLACEBO;
ADULT;
ARTICLE;
CLINICAL TRIAL;
COGNITION;
COGNITIVE DEFECT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIET SUPPLEMENTATION;
DISEASE SEVERITY;
DOUBLE BLIND PROCEDURE;
FEMALE;
FOLLOW UP;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MOOD;
NEGATIVE SYNDROME;
NEUROPSYCHOLOGICAL TEST;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SCHIZOIDISM;
SCHIZOPHRENIA;
SYMPTOMATOLOGY;
TREATMENT OUTCOME;
ADULT;
ANTIPSYCHOTIC AGENTS;
COGNITION DISORDERS;
DOUBLE-BLIND METHOD;
DRUG THERAPY, COMBINATION;
EICOSAPENTAENOIC ACID;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
NEUROLOGIC EXAMINATION;
PSYCHIATRIC STATUS RATING SCALES;
PSYCHOTIC DISORDERS;
SCHIZOPHRENIA;
SCHIZOPHRENIC PSYCHOLOGY;
TREATMENT OUTCOME;
|
|
EID: 0035190361
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ajp.158.12.2071 Document Type: Article |
|
Times cited : (262)
|
|
References (12)
|
